IVD Antibody Development Services for MR-proANP Marker

Creative Biolabs is a well-recognized expert in the field of antibody generation and production. Especially, we have launched a series of in vitro diagnostic (IVD) antibody development services for different infections and diseases. Scientific progress has resulted in the discovery of novel disease biomarkers to fulfill the need for a quicker, more specific and more accurate diagnosis. Particularly, we provide IVD antibody development services against the MR-proANP marker.

Pro-atrial natriuretic peptide (pro-ANP) is a stable fragment of atrial natriuretic peptide (ANP) precursor. ANP is a member of the natriuretic peptide family, this family has a class of structurally similar but genetically distinct peptides emerged as significant candidates for progress of diagnostic tools and therapeutic agents in cardiovascular diseases. ANP is mainly generated in the atrium of the heart and forms 98% of natriuretic peptides in the circulation. Mature ANP is produced from carboxyl-terminal amino acids 99–126 of the prohormone (pro-ANP) and the amino-terminal portion of pro-ANP (termed pro-ANP1–98) formed at the same molar ratio as ANP. Due to the much longer half-life of proANP 1–98 than mature ANP, proANP 1–98 has been suggested as a more credible analyte. Besides, results from a variety of high-performance liquid chromatography and competitive immunoassays analyses demonstrate that pro-ANP1–98 may be subject to further fragmentation.

Figure 1. The heart communicates with the brain, blood vessels, adrenals and kidneys by secreting 2 hormones, ANP and B-type natriuretic peptide (BNP). This cross-talk is essential for blood pressure regulation. (Kuhn, M. 2015)

MR-proANP Marker of Heart Failure

A great range of cardiovascular disorders that lead to the damage of the heart's capacity to fill or to pump out blood may finally result in HF. Traditionally clinical assessments of diagnosis such as physical examination and chest X-ray can be limited in precisely diagnosing HF. Therefore, as a novel method for diagnosis, HF biomarkers have dramatically impacted the way HF patients are evaluated and managed. A mid-regional sequence of proANP (MR-proANP) has proven to be a usable marker of HF. MR-proANP was found to be specifically predictive for the presence of acute HF as well as short-term and long-term death from acute and chronic HF. In addition, MR-proANP is as available as BNP for AHF diagnosis in dyspneic patients and offer extra clinical utility when BNP is difficult to interpret.

Figure 2. Receiver-operating characteristic curves for B-type natriuretic peptide (BNP) (green line), N-terminal pro–B-type natriuretic peptide (NT-proBNP) (red line), and mid-regional pro-atrial natriuretic peptide (MR-proANP) (blue line) for detecting acute heart failure. (B) Spearman's correlation between BNP and MR-proANP. (Maisel, A. 2010)

MR-proANP Marker of Sepsis

Sepsis is a potentially life-threatening complication of an infection. It happened when chemicals delivered into the bloodstream to withstand the infection trigger inflammatory responses throughout the body. The general signs and symptoms of sepsis contain fever, elevated heart rate and elevated breathing rate. Recently, pro-ANP has been recognized as a new marker in the field of sepsis. It has indicated that the MR-proANP was significantly raised in the plasma of sepsis patients as compared with patients without sepsis and healthy individuals.

Figure 3. Lifecycle of sepsis. (Morgenthaler, N. G. 2004)

IVD Antibody Development Services for MR-proANP Marker

In recent years, IVD technologies are undergoing rapid development. IVD antibodies have been extensively used for the diagnosis of numerous diseases, conditions, or infections. Numerous candidate biomarkers were introduced as specific biomarkers for discrimination of indolent and advanced diseases. As a pioneer in the antibody market, Creative Biolabs has provided a variety of IVD antibody development services for our global customers in the most high-quality and cost-effective way.

If you are interested in the services we provide, please feel free to contact us and get a quote.

Reference

1. Maisel, A. (2010). “Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.” Journal of the American College of Cardiology 55(19), 2062-2076.
2. Kuhn, M. (2015). “Cardiac Actions of Atrial Natriuretic Peptide New Visions of an Old Friend”. Circulation research 116(8), 1278-1280.
3. Morgenthaler, N. G. (2004). “Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study”. Critical Care 9(1), 1.

For Research Use Only.